



Finsbury Worldwide Pharmaceutical Trust PLC

Annual General Meeting

Samuel D. Isaly

OrbiMed Advisors LLC

July 15, 2010

Contents

- Fundamental Outlook and Performance: **Insistent Growth**
- Industry Outlook: **Valuations Near Historical Lows**
- Portfolio Review
- Large Cap Pharmaceuticals: **Company Fundamentals Count**
- Biotechnology
- Generic Pharmaceuticals
- Specialty Pharmaceuticals
- Considerations for Change
- OrbiMed Advisors: **Who We Are**
- Portfolio Exposure and Development
- UK Alternatives: **Few and Far Between**

Fundamental Outlook and Performance

Insistent Growth

Historical Performance from Fiscal Year End to the Annual General Meeting (NAV £)

Fiscal Year End	% Chg FY Ending	AGM Date	% Chg FYE to AGM
March 31, 2001	19.1	August 9, 2001	3.6
March 31, 2002	6.5 ◀	August 8, 2002	(29.4)
March 31, 2003	(34.5)	August 7, 2003	27.0
March 31, 2004	31.4 ◀	August 5, 2004	(9.7)
March 31, 2005	(13.9)	July 28, 2005	23.1
March 31, 2006	36.0 ◀	July 14, 2006	(14.3)
March 31, 2007	(9.6)	July 9, 2007	2.0
March 31, 2008	(5.7) ◀	July 23, 2008	8.3
March 31, 2009	23.7	July 17, 2009	(4.0)
March 31, 2010	24.8 ◀	July 15 2010 (est.)	(6.0)
March 31, 2011	??		

Source: Bloomberg

Long-Term Catalysts

Three Simple Reasons for Insistent Long Term Growth of Worldwide Pharmaceuticals and Biotechnology:

- Age
- Income
- Discovery

Fund Objectives

- Seek capital appreciation through a focused portfolio of long biotechnology and pharmaceutical stocks
- Invest globally to exploit market inefficiencies and to expand opportunity set of investments
- Reduce risk through extensive fundamental research, worldwide exposure, position limits, and balanced market capitalizations
- Offer a superior UK-listed opportunity for worldwide biotechnology and pharmaceutical exposure

Reasons to Invest in FWPT Now

- Proven investment performance
- Unmatched span of activity
- Unique structure of the Trust
- With US Healthcare reform behind us, stocks are poised for recovery
- Historic low valuation in pharmaceutical and biotechnology sectors
- Additional M&A expected over the next 12-18 months
- New product breakthroughs forthcoming
- Additional positive catalysts and newsflow expected in 2H10/2011
- The OrbiMed Advantage

Healthcare Reform Finally Passes

Overhang removed – Time to close the gap

- The prospect of healthcare reform has served as an overhang on the healthcare sector generally, leading to **underperformance** of healthcare stocks, including pharmaceuticals
- But on **March 23, 2010** President Obama signed the long awaited healthcare reform bill into law
- However, from Feb 2009 to bill passage, drug stocks underperformed the broader market by **~ 30%**

AMEX Pharma Index vs. S&P 500
~Relative Performance through 30 Jun 2010~



Healthcare Reform Finally Passes

Worst case scenario avoided completely

Market Concern

- Passage of a “public plan” insurance option that could see the government become a significantly larger payor/buyer of drugs leading to **price controls** in the U.S. pharmaceutical market

What Actually Passed

- Simply, an expansion of the current Medicaid program which dramatically increases eligibility
- Starting in 2014, coverage will be extended to an additional **30+ million** Americans
- Importantly, coverage will be executed via private, not public, exchanges
- Plus a positive for Biotech: biotechnology drugs were given 12 years of market exclusivity

OrbiMed's View

- In 2014, drug companies will be able to benefit from increased drug volumes
- Certain policies in the new legislation will put mild pressure on near-term earnings, such as:
 - expansion of the Medicaid rebate (2010)
 - new discounts on Medicare Part D drugs (2011)
 - an excise tax on drug makers starting (2011)
 - an excise tax on devices starting (2013)
- However, post 1Q10 results, the net impact on earnings was between **0-2%** for large cap pharma*
- Thus, overall, we expect a mild near-term financial impact to be offset by **volume gains** later
- As concerns over healthcare reform subside, **pharmaceutical industry should rally**



*EPS impact for 2010; exception was LLY at -7%

Winners and Losers Under Democratic Healthcare Reform

Winners	Neutral	Losers
Generics	Biotech	Large Pharma
Disease Management	Medical Devices	Managed Care
Healthcare IT	International Companies	
Hospitals		

- Emphasis on lower drug costs will benefit generics and hurt Big Pharma.
- Emphasis on preventive medicine and more efficient healthcare delivery may benefit disease management and healthcare IT companies. Hospitals could benefit from more insured lives.
- Managed care, especially Medicare plans, will suffer as government cuts reimbursement, though this may be offset by more covered lives from universal insurance coverage.
- Expect largely neutral impact on emerging biotech and devices (though Big Biotech may suffer some negative headwind due to reimbursement pressures).

Key Investment Themes By Sub-Sector

As of 30 June 2010

Structured Finance (10.1%)

- ▶ Basket of diversified companies with attractive equity like returns with debt protection
- ▶ Exposure to improvements in the credit market
- ▶ VRTX, INCY, ENDP

Major Biotechs (11.4%)

- ▶ PEG ratio of nearly 1, close to lowest levels in history
- ▶ High growth rates, in some cases accelerating further
- ▶ Low political and reimbursement risk
- ▶ Few patent expiration issues
- ▶ AMGN, GENZ, CELG

Emerging Biotech (11.6%)


- ▶ Continuing source of innovation and high R&D productivity
- ▶ Rampant M&A potential as Big Pharma tries to acquire biotech products and expertise
- ▶ Valuations at low end of historical range
- ▶ DNDN, VRTX, HGSI, MNTA

Tools/Diagnostics (1.5%)

- ▶ High growth opportunities
- ▶ Faster development times and lower regulatory hurdles vs. drugs
- ▶ ILMN

Diversified Healthcare (2.5%)

- ▶ Diversified away from specific product risks
- ▶ Taking advantage of accelerating growth in Chinese healthcare
- ▶ 1099 HK (Sinopharm)



Big Pharma (51.8%)

- ▶ Contrarian value plays
- ▶ High dividend yields
- ▶ Extremely selective to avoid looming patent expirations
- ▶ BMY, PFE, NVS

Generic / Specialty Pharma (17.2%)

- ▶ >\$120mm of U.S. branded drugs lose exclusivity by 2015
- ▶ Several quality branded names trade at rock-bottom valuations
- ▶ Secular growth story in Japan, catalyzed by fiscal pressures and regulatory changes
- ▶ AGN, SAWAI, TOWA, WCRX, HSP, WPI

Fundamental Outlook for 2010

- Large cap biotech likely to outperform big pharma
 - Superior growth/valuation characteristics
 - Patent expiration cycle peak in 2012 to weigh on big pharma
- M&A will remain a dominant theme for biotech (and some of our holdings)
- Hamburg’s confirmation as FDA commissioner (May 2009) likely to be a small net positive for the industry
- Fallout from Obama’s legislative actions still “TBD” as await new legal interpretation, but the “worst case” scenario has been avoided and a relief rally is expected

Industry Outlook


*Valuations Near
Historical Lows*

Long Term Historically Attractive Entry Point

Near term opportunity as healthcare reform overhang is lifted

Attractive Valuations Create Long Opportunities

(through 31 Dec 2009)



Healthcare PE Relative to S&P PE at Historical Low

(through 31 Dec 2009)



- Valuations across the healthcare sector have declined to historical lows after a nearly 10 year period of underperformance
- We believe this performance and valuation differential provides a significant opportunity to earn near-term returns across a variety of long positions

Why Invest in Healthcare Now?

Big Pharma Perfect Storm Catalyzes Acquisitions of Biotech Companies

Announce Date	Target	Acquirer	Deal Size	Premium Paid
05/21/09	Cougar Biotechnology	Johnson & Johnson	\$970 million	16%
03/12/09	CV Therapeutics	Gilead	\$1.4 billion	25%
02/27/09	Arana Therapeutics	Cephalon	\$210 million	69%
01/13/09	Targanta	Medicines Co.	\$50 million	72%
01/05/09	Indevus	Endo Pharmaceuticals	\$370 million	45%
11/24/08	Alpharma	King Pharmaceuticals	\$1.6 billion	54%
11/24/08	Omrix	Johnson & Johnson	\$465 million	18%
10/30/08	Genelabs	GlaxoSmithKline	\$57 million	430%
10/06/08	Imclone	Eli Lilly	\$6.5 billion	51%
09/01/08	Sciele Pharma	Shionogi	\$1.4 billion	57%
07/25/08	Acambis	Sanofi Aventis	£275 million	65%
07/23/08	Arius Research	Roche	CAD \$191 million	15%
07/15/08	Lev Pharmaceuticals	ViroPharma	\$443 million	49%
07/10/08	Speedel	Novartis	\$880 million	94%
07/08/08	SGX Pharmaceuticals	Eli Lilly	\$64 million	119%
07/07/08	APP Pharmaceuticals	Fresenius	\$3.6 billion	29%
07/03/08	Jerini	Shire	\$521 million	73%
06/23/08	Barrier Therapeutics	Stiefel Laboratories	\$148 million	136%
06/09/08	Third Wave Technologies	Hologic	\$580 million	7%
06/05/08	Tercica	Ipsen	\$665 million	104%
05/29/08	Kosan	Bristol-Myers	\$190 million	233%
05/12/08	Iomai	Intercell	\$189 million	128%
04/22/08	Sirtris	GlaxoSmithKline	\$720 million	84%

Historic Low Valuations for Major Biotech

Strong EPS Growth


Historical & Projected EPS Growth for Selected “Major Biotech”

As of 15/06/10	Market cap (\$bn)	2009	2010	2011	LTGR %	'10 P/E
Amgen	53	+8	+4	+7	+9	11x
Gilead Sciences	32	+49	+18	+7	+14	10x
Celgene	25	+33	+28	+23	+23	20x
Genzyme	13	-43	+12	+50	+19	20x
Biogen Idec	13	+13	+11	+6	+9	10x
Total Above	\$136 bn	~12%	~15%	~19%	~15%	~14x

Historic Low Valuations for Major Biotech

Comparative P/E Ratios

Comparative Forward P/E Multiples




¹AMEX Pharmaceutical Index; market-cap weighted index of fifteen widely held stocks in the pharmaceutical industry
²Market-cap weighted large-cap biotech index; AMGN, GILD, CELG, BIIB, GENZ

Source: Citigroup

Historic Low Valuations for Major Biotech

Comparative "PEG Ratios"

Comparative PEG Ratios



¹AMEX Pharmaceutical Index; market-cap weighted index of fifteen widely held stocks in the pharmaceutical industry

²Market-cap weighted large-cap biotech index; AMGN, GILD, CELG, BIIB, GENZ

Source: Citigroup

Portfolio Review

Major Subsectors (30 June 2010)

<u>Subsector</u>	<u>% of NAV</u>
Big Pharma	52%
Emerging Biotech	12%
Major Biotech	11%
Worldwide Generics	11%
Specialty Pharma	9%
Life Sciences & Tools	2%
Structured Finance	10%
Total	106%

Big Pharma (30 June 2010)

<u>Company</u>	<u>Country</u>	<u>% NAV</u>
Novartis	Switzerland	8.8
Johnson & Johnson	United States	7.8
Pfizer	United States	7.6
Merck	United States	7.5
Roche Holding	Switzerland	7.4
Bristol-Myers Squibb	United States	5.4
GlaxoSmithKline	United Kingdom	2.5
Sanofi-Aventis	France	2.5
Abbott Laboratories	United States	2.3
Subtotal Big Pharma		51.8

Major Biotech (30 June 2010)

<u>Company</u>	<u>Country</u>	<u>% NAV</u>
Amgen	United States	3.1
Genzyme	United States	2.6
Shire	United Kingdom	2.0
Celgene	United States	1.9
Gilead Sciences	United States	1.8
Subtotal Major Biotech		11.4

Emerging Biotech (30 June 2010)

<u>Company</u>	<u>Country</u>	<u>% NAV</u>
NPS Pharmaceuticals	United States	2.0
Dendreon	United States	1.4
Allos Therapeutics	United States	1.2
Momenta Pharmaceuticals	United States	1.1
Actelion	Switzerland	1.0
BioMarin Pharmaceutical	United States	1.0
Cubist Pharmaceuticals	United States	1.0
Elan	Ireland	1.0
Vertex Pharmaceuticals	United States	1.0
Human Genome Sciences	United States	0.9
Subtotal Emerging Biotech		11.6

Generics (30 June 2010)

<u>Company</u>	<u>Country</u>	<u>% NAV</u>
Sawai Pharmaceutical	Japan	2.7
Hospira	United States	2.6
Nichi-iko Pharmaceutical	Japan	2.5
Towa Pharmaceutical	Japan	2.5
Perrigo	United States	0.5
Subtotal Generics		10.8

Specialty Pharma & Life Science / Tools (30 June 2010)

<u>Company</u>	<u>Country</u>	<u>% NAV</u>
Sinopharm Medicine	China	2.5
Allergan	United States	1.9
Endo Pharmaceuticals	United States	1.5
Warner Chilcott	United States	1.5
Mitsubishi Tanabe Pharmaceutical	Japan	1.1
Medicines Co	United States	0.4
Subtotal Specialty Pharma		8.9

<u>Company</u>	<u>Country</u>	<u>% NAV</u>
Illumina	United States	1.5
Subtotal Life Sciences Tools & Services		1.5

Structured Finance (30 June 2010)

<u>Company</u>	<u>% NAV</u>
Angiotech Pharm Float 12/01/13	1.0
Dendreon Corp 4.75% 06/15/14	0.7
Incyte Corp 4.75 10/01/15	1.6
Elan Fin plc 8.75% 10/15/16	0.9
PhaRMA 19 PDL Royalty 10.25%	0.7
Endo Pharma 1.75% 04/15/15	0.5
VWR Fund Inc 10.25% 07/15/15	1.4
Vertex Milestone Monetization	2.3
PhaRMA 10 Cinacalcet Royalty B 15.5%	1.0
Subtotal Structured Finance	10.1

Finsbury Worldwide Pharmaceutical Trust

- Captures the best of the worldwide pharma sector
- Exposure to “Big Biotech” in the U.S.
- Participation in scientific advance worldwide
- Large liquid vehicle with historically little/no discount
- The “Third Force” in the U.K. market for pharmaceutical investors







Large Cap Pharmaceuticals

Company Fundamentals Count

Large Cap Pharmaceuticals – Fundamentals Count

- Stocks are trading at valuations that are at or near **generational lows**
- But all drugs stocks are “cheap” – so valuation is not enough
- The need to be **selective** and dissect which companies are doing the right thing is more important than ever given industry head winds: patent expirations, pipeline attrition, pricing pressures, etc.
- In other words, company **fundamentals** still matter – a lot
- Separation between the **“haves”** and the **“have nots”** is beginning to emerge:
 - New Product Flow
 - Emerging Pipelines
 - Exposure to Patent Cliff
 - Diversity (away from primary care market and small molecules)
 - Strong Management
 - Smart Acquisitions
 - Take-Out Candidate

Large Cap Pharmaceuticals – “Haves”

	Near Term Earnings Growth	New Product Flow	Late Stage Pipeline	Exposure to Patent Cliff	Diversity	Strong Management	Smart Acquisitions	Take-Out Candidate
 Bristol-Myers Squibb Company	✓	✓	✓	✗	✓	✓	✓	✓
 NOVARTIS	✓	✓	✓	✗	✓	✓	✓	✗
 Roche	✓	✗	✓	✓	✓	✓	✓	✗
 MERCK	✗	✓	✓	✓	✗	✓	✓	✗
 Johnson & Johnson	✗	✓	✓	✓	✓	✓	✓	✗
 Pfizer	✗	✗	✓	✗	✓	✗	✓	✗




Large Cap Pharmaceuticals – Case Study



Bristol-Myers Squibb

- ✓ Near Term Earnings Growth: top tier at >10% per annum to 2013
- ✓ New Product Flow: 5 products still growing at +20% or better
- ✓ Late Stage Pipeline: multiple blockbuster opportunities in late stage
- ✗ Patent Cliff: difficult (but manageable?) with >30% sales exposed
- ✓ Diversity: move into biologics and specialty care has been rapid
- ✓ Management: CEO + CFO prudence has been exemplary
- ✓ Smart Acquisitions: “string of pearls” strategy has led industry
- ✓ Take-Out Candidate: we predict that BMY will be the next large cap pharmaceutical company to be taken-over (after WYE and SGP)

Large Cap Pharmaceuticals – “Have Nots”

	Near Term Earnings Growth	New Product Flow	Late Stage Pipeline	Exposure to Patent Cliff	Diversity	Strong Management	Smart Acquisitions	Take-Out Candidate
 Abbott A Promise for Life	✓	✗	✗	✓	✗	✓	✓	✗
	✗	✓	✗	?	✓	✓	✗	✗
	✗	✗	✗	✗	✓	?	✓	✗
	✗	✗	✓	✗	✗	✗	✓	✗
 AstraZeneca	✓	✗	✗	✗	✗	✗	✗	✓
 Lilly	✓	✗	✗	✗	✗	✗	✗	✗

Biotechnology

Biotech Sector Overview

1. Healthcare reform overhang provides buying opportunity
 - The US Healthcare Reform legislation provides biotech drugs 12 years of patent exclusivity
2. New product breakthroughs forthcoming*
 - Prolia (\$5bn), Benlysta (\$2bn), Provenge (\$2bn), Telaprevir (\$5bn)
3. Historic low valuations for major biotech
 - Biotech stocks are trading at 14x 2010 P/E and at a PEG of <1
4. Continued strong M&A in sector
 - M&A environment continues to be robust with favorable valuation and acquisitive big pharmas
5. Positive catalysts and newsflow expected in 2H10/2011
 - Potential approvals in Benlysta, Bydureon, Qnexa

*OrbiMed peak sales estimates

New Product Breakthroughs Forthcoming

Several biotech blockbusters to be introduced soon

Product	Marketer	Indication	Launch Year	Revenue Potential
Denosumab	Amgen	Osteoporosis	2009	\$5 billion
Tyvaso	United Therapeutics	Pulmonary Hypertension	2009	\$200 million
Folotyn	Allos Therapeutics	T-cell Lymphoma	2009	\$500 million
Arzerra	Genmab/Glaxo	CLL	2009	\$500 million
Fampridine	Acorda	Multiple Sclerosis	2009	\$500 million
Cinryze	ViroPharma	Hereditary Angioedema	2009	\$250 million
Krystexxa	Savient	Gout	2010	\$500 million
Benlysta	HGS/Glaxo	Lupus	2010	\$2 billion
Provenge	Dendreon	Prostate cancer	2010	\$2 billion
Telaprevir	Vertex	Hepatitis C	2011	\$5 billion

Source: OrbiMed Advisors LLC

M&A Activity Continuing at a Steady Pace

Big pharma “perfect storm” catalyzes acquisitions

Announce Date	Target	Acquirer	Deal Size	Premium Paid
04/12/10	Javelin Pharmaceuticals	Hospira	\$140 million	64%
03/09/10	Facet Biotech	Abbott Laboratories	\$402 million	206%*
03/01/10	OSI Pharmaceuticals	Astellas Pharma	\$2.9 billion	41%
09/03/09	Sepracor	Dainippon Sumitomo	\$2.3 billion	28%
07/22/09	Medarex	Bristol Myers	\$2.4 billion	90%
07/14/09	Noven Pharmaceuticals	Hisamitsu	\$428 million	22%
05/29/09	CuraGen Corp	Celldex Therapeutics	\$95 million	50%
05/21/09	Cougar Biotechnology	Johnson & Johnson	\$970 million	16%
03/12/09	CV Therapeutics	Gilead	\$1.4 billion	25%
02/27/09	Arana Therapeutics	Cephalon	\$210 million	69%
01/30/09	Tepnel	Gen-Probe	\$132 million	126%
01/13/09	Targanta	Medicines Co.	\$50 million	72%
01/05/09	Indevus	Endo Pharmaceuticals	\$370 million	45%
11/24/08	Omrix	Johnson & Johnson	\$465 million	18%
10/30/08	Genelabs	GlaxoSmithKline	\$57 million	430%
10/06/08	Imclone	Eli Lilly	\$6.5 billion	51%
07/25/08	Acambis	Sanofi Aventis	£275 million	65%
07/23/08	Arius Research	Roche	CAD \$191 million	15%
07/21/08	Genentech	Roche	\$41.3 billion	16%
07/15/08	Lev Pharmaceuticals	ViroPharma	\$443 million	49%
07/10/08	Speedel	Novartis	\$880 million	94%
07/08/08	SGX Pharmaceuticals	Eli Lilly	\$64 million	119%
07/03/08	Jerini	Shire	\$521 million	73%

Generic Pharmaceuticals

Global Generics

Winning strategy: accentuate positives; eliminate negatives

Proper positioning is essential:

- US market
 - Leverage to product markets with improved pricing
 - Limited exposure to HCR-related net price cuts
 - Well contemplated biogenerics strategy
- EU & Asia
 - Operational and/or active f/x hedges
 - Limited exposure to EU net price cuts
 - Leverage cost advantages in Asia
 - Efficient supply chain management
- Best-positioned companies
 - Medium-sized, US-based players
 - Hospira; Watson
 - US-based OTC players
 - Perrigo



Global Generics

Tug-of-War has resulted in divergent price performance for major players




Pros:

- ▶ >\$120BN of US branded drugs lose exclusivity by 2015
- ▶ Biogeneric legislation clarifies commercialization pathway
- ▶ US generic pricing has improved
- ▶ US Healthcare Reform should drive volume increases

Cons:




- ▶ Net pricing in several EU countries has worsened
- ▶ Unfavorable F/X trends for many due to strong US\$
- ▶ Increased regulatory scrutiny having an impact
- ▶ Reimbursement changes create uncertainty

YTD performance of generics



Japanese Generics – An opportunity realized

- As early as 2005, we began to identify a secular theme in Japan related to generic pharmaceutical consumption
- The market was small compared to Western generic markets

	Share	
	Rx	\$
	17%	5%
	63%	13%
	43%	18%

Source: IMS YE 2006

Japanese Generics – An opportunity realized

– Penetration of generics was low for a host of reasons:



Cultural Norms (Japan is a “brand driven society”)



• Lack of Incentive for Patient



• Incentive for Physician / Hospitals to use Branded drugs



• Reputation of generic drugs (“cheap and nasty”)



• High government hurdle for generic approvals



• Lack of stable supply



Lack of information on generics for physician/patient



• Government protectionism


Japanese Generics – An opportunity realized

A sea change began to occur in Japan

- Government is concerned with the national healthcare budget and spending.
 - 1. Aging Population
 - 2. Increased ratio of citizens 75 years of age & older
 - 3. Medical expenses expected to grow >100% in <20 years
- Government began enacting new legislation
 - Rx Pad Changes (multiple)
 - Pharmacy Switching (change in measures)
 - Pharmacy Incentive Fees (increased + tiered)
 - Patient Co-Pays (reduced for generics)
 - Flat-rate insurance system for Elderly
- DPC Hospitals
- Promotion / DTC of Generic drugs
- Approval of generics to 2x / year



Government Target
30% market share
for generic Rx's by 2012



*New legislative changes have occurred every 2 years (2006,08,10)
--- all to promote increased use of generic drugs.*

Japanese Generics – An opportunity realized

Sales Acceleration --- since 2007

Sales Growth	
2007	CAGR Since '07

sawai

+10%

+18%




+8%

+12%



+11%

+26%




Japanese Generics – Alpha Generators



- “value added” generic drug maker in Japan
- focused on the GP market
- is in **expansion** phase, in terms of R&D, sales and marketing, and capacity



- best positioned to capitalize on increased generic usage at they are **#1 in pharmacies**
- most profitable generic drug company in Japan
- also increasing capacity



- focus on hospital market, especially “booming” **DPC market**
- are increasing MR activity in hospitals
- increasing capacity for specialty generics (injectables, cancer)

Market Cap

Oct 2007* →

Current →

Appreciation vs. Nikkei

\$630M

\$980M

+57%

+72%

\$500M

\$1.25B

+149%

+180%

\$650M

1.02B

+57%

+98%

*First investment made in FWPT

Japanese Generics – Alpha Generators

- Scorecard – Absolute + Relative Share Price Performance

	YTD			since Oct 2007		
	Absolute Total Return	Relative Total Return		Absolute Total Return	Relative Total Return	
		<i>vs. Japan Pharma Index (TPPHRM)</i>	<i>vs. Nikkei Index (NKY)</i>		<i>vs. Japan Pharma Index (TPPHRM)</i>	<i>vs. Nikkei Index (NKY)</i>
Sawai	50%	57%	58%	149%	180%	180%
Towa	32%	39%	40%	31%	72%	72%
Nichi-iko	27%	34%	35%	57%	98%	98%
TPPHRM	-7%		1%	-41%		0%
NKY	-8%	-1%		-41%	0%	

} Significant Share Price Outperformance

Specialty Pharmaceuticals

Specialty Pharma Brands

Conventional strategies have been compromised by generic players

“Me too” product strategy faces several challenges


- In general, undifferentiated products have experienced limited market uptake
 - In many cases, limited reimbursement hampers product launches
 - Entrenched generics make it difficult to gain meaningful market share
 - Early P-IV patent challenges from generic companies cap peak sales potential

Small “R”, Big “D” strategy no longer effective

- Branded and generic companies are now actively competing for niche proprietary compounds/products
 - Bidding wars ensue over attractive assets compromising ROI
 - Companies with capital constraints settle for subpar assets increasing development and commercial risks

As a result, companies with established, differentiated, longer duration franchises garner premium valuation

2011 P/E of Specialty Pharma universe



Specialty Pharma Brands

Winning Strategy: Play the extremes

➤ Buy high-quality names with premium valuation

- Allergan; Shire
 - Stable, enduring franchises
 - Catalyst-laden
 - Potential acquisition targets



➤ Buy quality names with very attractive valuation

- Endo; Warner Chilcott
 - Rock-bottom valuation
 - Solid cash flow
 - Contrarian



Considerations for Change

FWPT

- Inception in April 1995
- Additional fundraisings in 1996, 2004 and 2009 (warrant exercise)
- Total proceeds from formal fundraisings of £171.2 million
- Proceeds from share issuance of £21.5 million
- Cumulative 70 million shares placed
- Share repurchases totaling £122.8 million
- Cumulative 24 million shares repurchased
- Current Net Assets of £300 million

FWPT: Defining Initial Characteristics

- Worldwide
- Pharmaceutical
- Large Capitalization Orientation
- Finsbury Brand Existed at the Time
- Alternative to GlaxoSmithKline and AstraZeneca

FWPT: Market Value Rank Among Investment Trusts

Date	Value (£ mil.)	Rank
Dec 1995	18	NA / NA
Dec 2000	246	NA / NA
Dec 2005	312	46 / 248
Dec 2009	279	58 / 284
Feb 2010	292	56 / 283

FWPT: Evolution and Broadening of Initial Mandate

Date	Big Pharma	Specialty Pharma	Big Biotech	Specialty Biotech	Generics	Molecular Diagnostics	Other	Structured Finance	Total
Mar-96	45.1%	7.3%	13.2%	34.4%	0.0%	0.0%	0.0%	0.0%	100.0%
Mar-01	57.3%	9.1%	16.2%	17.4%	0.0%	0.0%	0.0%	0.0%	100.0%
Mar-06	37.3%	6.2%	22.6%	29.8%	0.0%	4.1%	0.0%	0.0%	100.0%
Mar-09	33.3%	0.0%	23.0%	29.3%	9.2%	3.4%	0.0%	1.8%	100.0%
Feb-10	36.4%	7.4%	12.3%	17.4%	14.1%	2.3%	0.0%	10.1%	100.0%

FWPT: Equity Market Values of Healthcare Segments (\$ bil.)

Date	Big Pharma	Big Biotech	Specialty Biotech	LS Tools / Services	Medical Devices	Healthcare Services	Total
Dec-95	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dec-00	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dec-05	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dec-09	1,972	54	154	94	512	418	3,204
Feb-10	1,927	57	158	96	510	419	3,167

FWPT: Representative Companies of “New” Segments (\$ bil.)

Life Sciences Tools and Services

Thermo Fisher (TMO): \$20 bil.

Life Technologies (LIFE): \$9 bil.

Waters (WAT): \$6 bil.

Millipore (MIL): \$5 bil.

Illumina (ILMN): \$5 bil.

Medical Devices

Medtronic (MDT): \$48 bil.

Baxter (BAX): \$35 bil.

Covidien (COV): \$24 bil.

St. Jude Medical (STJ): \$13 bil.

Align Technology (ALGN): \$1 bil.

Healthcare Services

United Health (UNH): \$40 bil.

Medco Health (MHS): \$30 bil.

Wellpoint (WLP): \$27 bil.

Aetna (AET): \$13 bil.

Cigna (CI): \$9 bil.

The Worldwide Healthcare Trust PLC

- Full Participation in Healthcare Worldwide;
Expansion of Investable Universe by 40%
- No Longer an Alternative to just GlaxoSmithKline
and AstraZeneca
- Consistent with OrbiMed Strength, and
Application in Other Portfolios
- Better Prospective Returns
- “Finsbury” Branding no Longer Relevant
- Re-energized Marketing
- Possibility of Additional Fundraising

FWPT: Special Considerations

Change of Benchmark:

Switch to MSCI World Health

Reasons to Invest in FWPT Now

- Proven investment performance
- Unmatched span of activity
- Unique structure of the Trust
- With US Healthcare reform behind us, stocks are poised for recovery
- Historic low valuation in pharmaceutical and biotechnology sectors
- Additional M&A expected over the next 12-18 months
- New product breakthroughs forthcoming
- Additional positive catalysts and newsflow expected in 2H10/2011
- The OrbiMed Advantage

OrbiMed Advisors

Who We Are

Why Invest with OrbiMed?

A premier institutional healthcare investment firm with proven results

- A premier investment firm focused exclusively on the healthcare sector, with approximately \$5 billion in assets under management
- Unmatched span of activity: healthcare investments across all major geographies, subsectors and company stages
- Over 30 investment professionals across four offices provide a potent combination of scientific expertise, analytical skills and industry experience
- Proven investment performance over a significant period of time
- Stable organization with consistent strategy and leadership for 15+ years
- Investor-friendly and strong corporate governance:
 - ▶ Never utilized side pockets, gates, or other liquidity restrictions
 - ▶ S.E.C. registered firm, all funds use a third-party accountant/administrator
 - ▶ Very high level of employee investment; personal healthcare trades restricted

OrbiMed Investment Professionals

Partners

Samuel D. Isaly, *Managing Partner*
 B.A.: Princeton University
 M.Sc. (Econ.): London School of Economics

Sven H. Borho, CFA, *Partner*
 University of Bayreuth
 M.Sc. (Econ.): London School of Economics

Carl Gordon, Ph. D., CFA, *Partner*
 B.A.: Harvard University
 Ph.D.: Molecular Biology, M.I.T.

Michael Sheffery, Ph.D., *Partner*
 B.A.: Princeton University
 Ph.D.: Molecular Biology, Princeton Univ.

Jonathan Silverstein, J.D., *Partner*
 B.A.: Denison University
 J.D./M.B.A.: Univ. of San Diego

W. Carter Neild, CFA, *Partner*
 B.A.: Emory University
 M.B.A.: University of Chicago

Geoffrey Hsu, CFA, *Partner*
 A.B.: Harvard University
 M.B.A.: Harvard University

Public Equity

Richard Klemm, Ph.D., CFA
 B.A.: University of California, Berkeley
 Ph.D.: Molecular Biology, M.I.T.

Trevor Polischuk, Ph.D.
 Ph.D.: Neuropharmacology, Queen's Univ.
 M.B.A.: Queen's University

Kuhn Tsai, M.D.
 A.B.: Harvard University
 M.D./M.B.A.: University of Chicago

William Sawyer
 B.S.: Pharmacology, Rutgers University
 M.B.A.: New York University

C. Scotland Stevens
 B.S.: UNC Chapel Hill
 M.B.A.: University of Pennsylvania

Tadd Wessel
 B.A.: Biology, Princeton University

Matthew Rizzo
 B.S.: State University of New York, Buffalo
 M.B.A.: Duke University

Jung Ryu
 B.A.: Dickinson College

Private Equity

Samuel Wertheimer, Ph.D.
 B.A.: Johns Hopkins University
 M.P.H.: Yale School of Public Health
 Ph.D.: Immunology, NYU School of Medicine

David Bonita, M.D.
 A.B.: Harvard University
 M.D./M.B.A.: Columbia University

Rishi Gupta, J.D.
 B.A.: Biochemical Sciences, Harvard Univ.
 J.D.: Yale Law School

Chau Khuong
 B.S.: Biology, Yale College
 M.P.H.: Yale School of Public Health

David Darst
 A.B.: Harvard University
 M.B.A.: Harvard University

Vivian Liu
 B.A.: Biology, Stanford University

Venture Partners

Klaus Veitinger, M.D., Ph.D.
 M.B.A.: INSEAD, France
 M.D./Ph.D.: University of Heidelberg

Asia Private Equity

Nancy Chang, Ph.D.
 B.S.: National Tsing Hua University
 Ph.D.: Biological Chemistry, Harvard Univ.

Jonathan Wang, Ph.D.
 M.B.A.: Stanford University
 Ph.D.: Molecular Neurobiology, Columbia Univ.

Sunny Sharma, M.D.
 M.B.A.: I.I.M., Bangalore
 M.D.: Christian Medical College, Ludhiana

Swati Bansal, C.F.A.
 B.E.: BMS College of Engineering, Bangalore
 M.B.A.: ICFAI University, Hyderabad

Lefei Sun, Ph.D.
 B.S.: Tsinghua University
 Ph.D.: Neurosciences, Johns Hopkins Univ.

Trency Gu, Ph.D.
 B.S.: Shanghai Jiaotong University
 Ph.D.: Shanghai Jiaotong University

Thomas Schuetz, M.D., Ph.D.
 M.D.: Harvard Medical School
 Ph.D.: Genetics, Harvard

Trading

Andrew Kanarek, CFA
 B.S.: New York University
 B.E.: Stevens Institute of Technology

Jason Kahn
 B.S.: University of Wisconsin

Kevin Olsen
 B.S.: New York University

Finance

Eric Bittelman, CPA
 B.A.: S.U.N.Y Stony Brook
 M.B.A.: Baruch College


Donald Bennett, CPA
 B.A.: St. Johns University

Kerrie Swingle
 B.A.: Drew University

William Price
 B.S.: Villanova University
 M.B.A.: Fordham University

Emily Fung
 B.S.B.A.: Washington University

Globally Integrated Investment Platform



Source: OrbiMed Advisors

Portfolio Exposure and Development

Portfolio Development


Period Ending 30 June 2010

Date	Number of Names *	Total Net Assets
31 March 2005	37	£ 226 million
31 March 2006	41	£ 323 million
31 March 2007	31	£ 267 million
31 March 2008	36	£ 221 million
31 March 2009	37	£ 260 million
31 March 2010	38	£ 341 million
June 30 2010	37	£ 307 million

* Excluding Options and Structured Finance

Portfolio Exposure

As of 30 June 2010



<u>Region</u>	<u>Large Cap</u>	<u>Small/Mid</u>
North America	44.5%	25.5%
Europe	23.1%	1.9%
Far East	0.0%	11.5%

Portfolio Development

Fiscal Year-to-Date as of 30 June 2010 (Common Equities)

Additions	Deletions
Actelion	Genmab
GlaxoSmithKline	Genomic Health
Human Genome Sciences	InterMune
Mitsubishi Tanabe Pharma	Mylan
Sanofi-Aventis	OSI Pharmaceuticals
	Teva Pharmaceutical
	Buy/Sell

Portfolio Development

Fiscal Year Ending 31 March 2010 (Structured Finance)

Additions	Deletions
Angiotech Pharm Float 12/01/13	Affymetrix 3.50% 01/15/38
Dendreon Corp 4.75% 06/15/14	Elan Fin plc 7.75% 11/15/11
Elan Fin plc 8.75% 10/15/16	
Endo Pharma 1.75% 04/15/15	
Incyte Corp 4.75% 10/01/15	
PhARMA 10 Cinacalcet Royalty B 15.50%	Buy/Sell
PhARMA 19 PDL Royalty 10.25%	Incyte Corp 3.50% 02/15/11
Salix Pharmaceuticals 5.50% 08/15/28	KV Pharma 2.50% 05/16/33
Shire Pharm PLC 2.75% 4/25/14	Medarex 2.25% 05/15/11
Vertex Milestone Monetization	Nektar Convert 3.25% 09/28/12
VWR Fund Inc 10.25% 07/15/15	OSI Pharma 3.00% 01/15/38

Portfolio Development

Fiscal Year-to-Date as of 30 June 2010 (Structured Finance)

Additions	Deletions
	Salix Pharmaceuticals 5.5% 08/15/28
	Shire PLC 2.75% 4/25/14
	Buy/Sell

Major Movers

Fiscal Year Ending 31 March 2010

Largest Gains	% Chg (\$)	Largest Losses	% Chg (\$)
InterMune	109.1	Medicines Co	(64.7)
XOMA	84.9	Genomic Health	(28.3)
Sinopharm Medicine Holding	80.8	Biogen Idec	(20.2)
BioMarin Pharmaceutical	80.3	Genzyme	(11.0)
Incyte Corp 4.75 10/01/2015	80.0	Nektar Therapeutics	(8.9)
Salix Pharmaceuticals 5.5% 08/15/2028	72.4	GlaxoSmithKline	(7.3)
Par Pharmaceutical	65.9	Gen-Probe	(6.9)
Shire	54.6	Warner Chilcott	(4.3)
Affymetrix 3.50% 01/15/38	48.8	Nichi-iko Pharm	(4.3)
United Therapeutics	48.7	Schering-Plough	(3.3)

Major Movers


Fiscal Year Ending 31 March 2010

Largest Gains	\$ mn	Largest Losses	\$ mn
Novartis	11.6	Genzyme	(3.7)
Sinopharm Medicine Holding	8.7	Biogen Idec	(2.1)
Shire	7.8	Medicines Co	(1.9)
Mylan	6.6	GlaxoSmithKline	(1.5)
Johnson & Johnson	6.5	Genomic Health	(1.3)
Roche Holding	6.2	Gen-Probe	(1.3)
InterMune	6.2	Nichi-iko Pharm	(0.4)
Dendreon	5.6	Warner Chilcott	(0.4)
Vertex Pharmaceuticals	5.5	Schering-Plough	(0.4)
BioMarin Pharmaceutical	5.2	Nektar Therapeutics	(0.1)

Note: Relative to approximately \$550 million gross assets.

FWPT Since Inception

Cumulative Growth through 30 June 2010 (£ - Total Return)



FWPT Since Inception

Cumulative Growth through 30 June 2010 (\$ - Total Return)




UK Alternatives


Few and Far Between

Worldwide “Big Pharma” Opportunity

Market Caps over \$30 bn as of June 2010



Finsbury Worldwide Pharmaceutical Trust vs. AstraZeneca and GlaxoSmithKline - Cumulative Share Price Change Inception to June 2010



And Then There Were None?

Acquired U.K. Companies	Acquirer	Date	Deal Size (£ mn)
Amersham	General Electric	04/08/04	5,939
Warner-Chilcott	Warren Acquisition	01/06/05	1,600
Celltech	UCB	05/18/04	1,372
Cambridge Antibody Tech.	AstraZeneca	05/15/06	702
PowderJect	Chiron	08/05/03	468
Neutec Pharma	Novartis	06/07/06	305
Acambis	Sanofi-Aventis	07/25/08	275
Xenova Group	Celtic Pharma	09/20/05	97
Tepnel Life Sciences	Gen-Probe	01/30/09	63
British Biotech	Vernalis	10/22/03	47

And Then There Were None? (continued)

Remaining U.K. Companies	Shares O/S (mil)	Price (£) 30-06-2010	Market Value (£ mil)
Shire Plc	562	1,374	7,724
Hikma Pharmaceuticals Plc	193	714	1,378
BTG Plc	258	199	514
Abcam Plc	36	1,225	440
GW Pharmaceuticals Plc	130	119	154
Vectura Group Plc	326	45	147
Prostrakan Group Plc	202	67	136
Oxford BioMedica Plc	545	11	60
Immupharma Plc	81	72	58
Renovo Group Plc	190	28	53
Proximagen Group Plc	57	78	44
Sinclair Pharma Plc	162	27	43
Proteome Sciences Plc	192	20	39
Antisoma Plc	630	6	37
Allergy Therapeutics Plc	311	12	36
Vernalis Plc	100	31	31

The total market value of the remaining U.K. Biotech is about £10 billion.